100 filings
Page 2 of 5
ARS
d5d nb4tu
20 Oct 23
Annual report to shareholders
4:15pm
8-K
4dgq3cdy2li04 nunac
10 Oct 23
Shuttle Pharma to Participate in the Lytham Partners Fall 2023 Investor Conference
9:00am
8-K
xrttctf
5 Oct 23
Entry into a Material Definitive Agreement
4:10pm
8-K
i0e5gz4ifmks0q7xpi58
25 Sep 23
Shuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma
9:00am
8-K
tznmt9vqrcv4v
7 Sep 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
9:20am
424B3
3qpnaipu9c3 okmm1dv9
24 Aug 23
Prospectus supplement
2:00pm
8-K
robkmo
15 Aug 23
Shuttle Pharmaceuticals Provides Second Quarter 2023 Corporate Update
9:00am
8-K
c55nvx89mrsiv5
3 Aug 23
Shuttle Pharmaceuticals Completes Manufacturing of Active Pharmaceutical Ingredient (API) for Use in Clinical Trial
9:00am
DEF 14C
wuh45yb76fh44 m3s
16 Jun 23
Information statement
6:30am
PRE 14C
owtiz7qq19 7pdm
5 Jun 23
Preliminary information
4:29pm
8-K
oteejgoab2z l3hlsw
5 Jun 23
Entry into a Material Definitive Agreement
8:10am
8-K
lmfpfke7cm ycsp7h
26 May 23
Shuttle Pharmaceuticals Provides First Quarter 2023 Corporate Update
9:00am
8-K
bvupe5l
17 May 23
Shuttle Pharmaceuticals to Participate in the Lytham Partners Spring 2023 Investor Conference
9:00am
NT 10-Q
s2q8g9n8sxr chw
15 May 23
Notice of late quarterly filing
5:26pm
8-K
wtfztj73b4r3akjdxfsf
11 May 23
Entry into a Material Definitive Agreement
8:12am
8-K
qjs jk09k
3 May 23
Departure of Directors or Certain Officers
4:10pm
8-K
ip5z pzw7nxv
22 Mar 23
Entry into a Material Definitive Agreement
9:00am